Journal of Internal Medicine Concepts & Practice >

2024 , Vol. 19 >Issue 03: 185 - 187

DOI: https://doi.org/10.16138/j.1673-6087.2024.03.06

Case report

Acute myeloid leukemia with CEBPA double mutation combined with GATA2 germline mutation: one case report

  • AN Huihui ,
  • WU Tao ,
  • LI Yunyun ,
  • LIU Wenhui ,
  • TIAN Sirui ,
  • LIU Yang ,
  • GAO Mingmin
Expand
  • 1. The Second Hospital of Lanzhou University (the Second Clinical Medical College), Lanzhou 730030, China
    2. Department of Hematology, the 940th Hospital of the Joint Logistics Support Force of Chinese People’s Liberation Army, Lanzhou 730050, China

Received date: 2023-12-25

  Online published: 2024-09-09

Fold

Abstract

The patient was diagnosed as acute myeloid leukaemia with CEBPA double mutation, GATA2 and IKZF1 mutation in 2021, and relapsed after giving two courses of IA treatment (idarubicin, cytosine arabinoside). There was transient remission after four additional courses of azacitidine combined with venetoclax. The patient relapsed again due to lack of regular treatment. This paper mainly analyses the therapeutic and prognostic role of CEBPA double mutation combined with GATA2 germline mutation in acute myeloid leukaemia.

Key words： GATA2 mutation; Acute myeloid leukaemia; Haematopoietic stem cell transplantation; Haematological malignancies; CEBPA

Cite this article

AN Huihui , WU Tao , LI Yunyun , LIU Wenhui , TIAN Sirui , LIU Yang , GAO Mingmin . Acute myeloid leukemia with CEBPA double mutation combined with GATA2 germline mutation: one case report[J]. Journal of Internal Medicine Concepts & Practice, 2024 , 19(03) : 185 -187 . DOI: 10.16138/j.1673-6087.2024.03.06

References

[1] Newell LF, Cook RJ. Advances in acute myeloid leukemia[J]. BMJ, 2021, 375:n2026.
[2] Calvo KR, Hickstein DD. The spectrum of GATA2 deficiency syndrome[J]. Blood, 2023, 141(13): 1524-1532.
[3] Belohlavkova P, Hrochova K, Fatorova I, et al. MonoMAC syndrome with GATA2 novel mutation[J]. Leuk Res Rep, 2022, 18:100346.
[4] Mulet-Lazaro R, van Herk S, Erpelinck C, et al. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML[J]. Blood, 2021, 138(2): 160-177.
[5] Bullinger L. CEBPA mutations in AML[J]. Blood, 139(1): 6-7.
[6] Russo V. Cholesterol: a putative oncogenic driver for DLBCL[J]. Blood, 2022, 139(1): 5-6.
[7] West RR, Bauer TR, Tuschong LM, et al. A novel GATA2 distal enhancer mutation results in MonoMAC syndrome in 2 second cousins[J]. Blood Adv, 2023, 7(20): 6351-6363.
[8] Wakita S, Sakaguchi M, Oh I, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia[J]. Blood Adv, 2022, 6(1):238-247.
[9] Taube F, Georgi JA, Kramer M, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome[J]. Blood, 2022, 139(1): 87-103.
[10] Ren H, Hong M, Feng J, et al. GATA2 mutant variant allele frequency may reflect prognosis in Chinese adult patients with de novo cytogenetically normal acute myeloid leukemia[J]. Biomol Biomed. 2024. Epub ahead of print.
[11] 黄佳瑜, 刘为星, 连芸, 等. 标准剂量IA方案诱导治疗242例初诊急性髓系白血病的临床观察[J]. 中华血液学杂志, 2018, 39(4):331-335.
[12] 张露雅. 去甲氧柔红霉素、柔红霉素分别联合阿糖胞苷诱导治疗初治成人急性髓系白血病的疗效及预后分析[J]. 罕少疾病杂志, 2022, 29(7):107-109.
[13] 韦梦红, 夏海龙. venetodax 联合阿扎胞苷治疗初诊不适合强化疗的急性髓系白血病患者的疗效观察[J]. 中国现代医生, 2024, 62(1):74-77.
[14] Morsia E, McCullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia[J]. Am J Hematol, 2020, 95(12): 1511-1521.
[15] Mishra R, Zokaei Nikoo M, Veeraballi S, et al. Venetoclax and hypomethylating agent combination in myeloid malignancies[J]. Int J Mol Sci, 2023, 25(1):484.
Options
Outlines

/

〈 〉